About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site         Guidelines at Diagnosis | About Clinical Trials            How to Help!

Patients Against Lymphoma

 

Follicular Lymphoma >  ASCO 2012 - MCL abstracts

Last update: 05/30/2012

Compiled from ASCO 2012 abstracts: Lymphoma | CLL
Comments or Questions?
  1. Cost-effectiveness analysis of bendamustine plus rituximab versus CHOP-R in treatment-naive patients with mantle cell (MCL) and indolent lymphomas (IL). | 2012 ASCO Annual Meeting Abstracts
     
  2. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. | 2012 ASCO Annual Meeting Abstracts
     
  3. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. | 2012 ASCO Annual Meeting Abstracts
     
  4. A retrospective study analyzing activity of ofatumumab in blastic variant mantle cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
     
  5. Expression pattern and biologic relevance of Bcl-2 and Mcl-1 in pulmonary neuroendocrine tumors. | 2012 ASCO Annual Meeting Abstracts
     
  6. Improving outcomes in mantle cell lymphoma patients treated with R-CHOP using autologous transplant. | 2012 ASCO Annual Meeting Abstracts
     
  7. A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). | 2012 ASCO Annual Meeting Abstracts
     
  8. Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.
  9. Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL).
  10. Pharmacokinetics (PK) of bendamustine when administered in combination with rituximab in patients with non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).
  11. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. | 2012 ASCO Annual Meeting Abstracts
     
  12. Phase I trial of obatoclax mesylate in combination with bortezomib for treatment of relapsed multiple myeloma. | 2012 ASCO Annual Meeting Abstracts
     
  13. Expression of mTOR in diffuse large B-cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
     
  14. Impact of lower chemotherapy dose on treatment outcome and survival of patients with advanced Hodgkin lymphoma: Single institution experience. | 2012 ASCO Annual Meeting Abstracts
     
  15. Natural history and clinical prognosis of in situ mantle cell lymphoma. | 2012 ASCO Annual Meeting Abstracts
     
  16. Unusual primary presentations of mantle cell lymphoma in the urinary tract and testes. | 2012 ASCO Annual Meeting Abstracts
     
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright 2004,  All Rights Reserved.